Loading...
Loading...
AKBA| Name | Value |
|---|---|
| Revenues | 55.2M |
| Cost of Revenue | -3.1M |
| Gross Profit | 58.3M |
| Operating Expense | 63.4M |
| Operating I/L | -5.1M |
| Other Income/Expense | -2.4M |
| Interest Income | 0.0M |
| Pretax | -7.6M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -8.8M |
Akebia Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutics for kidney diseases. Its lead product, vadadustat, is an oral therapy in Phase III development for treating anemia due to chronic kidney disease in adult patients. The company also offers Auryxia, a ferric citrate used to control serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, and for treating iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.
